重症监护医学
医学
抗生素耐药性
预期寿命
抗菌剂
医疗保健
疾病负担
全球卫生
抗生素
疾病
环境卫生
公共卫生
经济增长
生物
人口
内科学
护理部
微生物学
经济
作者
Ramanan Laxminarayan,Precious Matsoso,Suraj Pant,Charles Brower,John‐Arne Røttingen,Keith P. Klugman,Sally C. Davies
出处
期刊:The Lancet
[Elsevier]
日期:2016-01-01
卷期号:387 (10014): 168-175
被引量:1061
标识
DOI:10.1016/s0140-6736(15)00474-2
摘要
Recent years have seen substantial improvements in life expectancy and access to antimicrobials, especially in low-income and lower-middle-income countries, but increasing pathogen resistance to antimicrobials threatens to roll back this progress. Resistant organisms in health-care and community settings pose a threat to survival rates from serious infections, including neonatal sepsis and health-care-associated infections, and limit the potential health benefits from surgeries, transplants, and cancer treatment. The challenge of simultaneously expanding appropriate access to antimicrobials, while restricting inappropriate access, particularly to expensive, newer generation antimicrobials, is unique in global health and requires new approaches to financing and delivering health care and a one-health perspective on the connections between pathogen transmission in animals and humans. Here, we describe the importance of effective antimicrobials. We assess the disease burden caused by limited access to antimicrobials, attributable to resistance to antimicrobials, and the potential effect of vaccines in restricting the need for antibiotics.
科研通智能强力驱动
Strongly Powered by AbleSci AI